Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporat

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the ana

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concer

Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeut

Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the en

RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform

US stock futures rise, Nasdaq 100 up 1%. Datadog (DDOG) downgraded, pre-market trading. Other declin

Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform a

Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the c

NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment

Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW

NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics

Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the

HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a

Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead d

Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts work

ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora The

US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech s

US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks dow

Neumora Therapeutics said on ‌Monday it would stop developing its ​depression drug after ​two late-s

Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeut

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue developm

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clin

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.30) per share which beat the ana

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topl

U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a cl

LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights l

Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and main

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains

Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) was the target of some unusual options t

Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the

Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the a

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable

LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics

William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-51

William Blair analyst Myles Minter upgrades Neumora Therapeutics (NASDAQ:NMRA) from Market Perfor

Leerink Partners analyst Marc Goodman initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) wi

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationK

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningfu